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Abstract
Background:  The routine use of natiuretic peptides in severely 
dyspneic patients has recently been called into question. We hy-
pothesized that the diagnostic utility of Amino Terminal pro Brain 
Natiuretic Peptide (NT-proBNP) is diminished in a complex elderly 
population.
Methods:    We  studied  502  consecutive  patients  in  whom  NT-
proBNP values were obtained to evaluate severe dyspnea in the 
emergency department. The diagnostic utility of NT-proBNP for 
the diagnosis of congestive heart failure (CHF) was assessed uti-
lizing several published guidelines, as well as the manufacturer’s 
suggested age dependent cut-off points.
Results:  The area under the receiver operator curve (AUC) for 
NT-proBNP was 0.70. Using age-related cut points, the diagnostic 
accuracy of NT-proBNP for the diagnosis of CHF was below prior 
reports (70% vs. 83%). Age and estimated creatinine clearance cor-
related directly with NT-proBNP levels, while hematocrit correlat-
ed inversely. Both age > 50 years and to a lesser extent hematocrit 
< 30% affected the diagnostic accuracy of NT-proBNP, while renal 
function had no effect. In multivariate analysis, a prior history of 
CHF was the best predictor of current CHF, odds ratio (OR) = 45; 
CI: 23-88.
Conclusions:  The diagnostic accuracy of NT-proBNP for the eval-
uation of CHF appears less robust in an elderly population with 
a high prevalence of prior CHF. Age and hematocrit levels, may 
adversely affect the diagnostic accuracy off NT-proBNP.
Keywords:  Congestive Heart Failure; Natriuretic peptides; Diag-
nosis; Elderly Patients
Introduction
Congestive heart failure (CHF) is a major cause of death and 
disability worldwide. In the United States alone there are an 
estimated 550,000 new cases of CHF yearly and it is pro-
jected that 10 million patients will have symptomatic heart 
failure within the next 30 years [1]. The economic cost of 
CHF is estimated at $56 billion per year, 70% of which is 
spent on hospital utilization.
Diagnosing CHF by clinical exam can be challenging 
in patients with multiple co-morbidities [2], but its accuracy 
is paramount both for patient care and the appropriate utili-
zation of hospital resources. A careful history and clinical 
examination combined with additional laboratory data from 
currently available natriuretic peptide assays may provide 
the optimal balance of sensitivity and specificity [3] in the 
diagnosis of CHF. Natriuretic peptide testing has been FDA 
approved since 2002 and is now considered a Class IIa/Level 
of Evidence A recommendation for use in the evaluation of 
dyspnea in the emergency department according to current 
CHF guidelines [4].
Although  natriuretic  peptides  are  well  studied  in  the 
evaluation of CHF and offer value independent of physician 
decision making [2-8], recent data have questioned the util-
ity of routine natriuretic peptide determinations in severely 
dyspneic patients to improve clinical outcomes or diminish 
hospital resource utilization [9]. Additionally, the relation-
ship between natriuretic peptides and the severity of heart 
failure appears less clear in patients with chronic kidney dis-
ease (CKD) and those with a history of prior CHF [10, 11].
The appropriate cut-off values for Amino Terminal pro 
Brain  Natiuretic  Peptide  (NT-proBNP)  for  the  diagnosis 
CHF were originally derived from the N-Terminal Pro BNP 
Investigation  of  Dyspnea  in  the  Emergency  Department 
(PRIDE) Study [7]. Broader standards were then put forth 
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from pooled data in the International Collaborative of NT-
proBNP (ICON) Study [8]. We undertook the present study 
to assess the diagnostic utility of NT-proBNP in a predomi-
nantly elderly, medically complex population presenting to 
the emergency room with dyspnea using accepted age-relat-
ed cut points. We postulated that the utility of NT-proBNP in 
CHF would be diminished in elderly patients with multiple 
baseline cardiopulmonary co-morbidities.
Methods
The study protocol was approved by our institutional review 
board. Data was reviewed for consecutive patients present-
ing to a university affiliated community hospital and have 
previously been presented at the 2006 American College of 
Cardiology  Meeting  [12]. We  retrospectively  studied  550 
consecutive  patients  presenting  to  our  emergency  depart-
ment  in  whom  NT-proBNP  values  were  obtained  for  the 
evaluation of dyspnea. Only subjects with incomplete labo-
ratory results or missing clinical data were excluded from 
study. A total of 502 subjects were eligible for enrollment.
Data  were  collected  and  analyzed  independently  for 
each subject. Clinical characteristics including baseline de-
mographics, presenting complaints, symptoms, signs, past 
medical history, medication use and examination findings 
were tabulated by a research assistant. Laboratory data and 
investigations including basic metabolic profile, complete 
blood count, electrocardiogram and chest x-ray were also re-
corded. Creatinine clearance was estimated using the Modi-
Table 1. Demographics and Clinical Characteristics in the Entire Cohort
CHF: congestive heart failure; MI: myocardial infarction; PTCA: percutaneous coronary intervention; CABG: coronary artery 
bypass grafting; COPD: chronic obstructive pulmonary disease; PE: pulmonary embolus; ACE-I: angiotensin converting en-
zyme inhibitor; ARB: angiotensin receptor blocker; eGFR: estimated glomerular filtration rate. P value compares those with and 
without a final diagnosis of CHF.
 
Total (%)  (-) CHF (%)  (+) CHF (%)  p-value 
Demographics
    Age (years)
    (mean/range) 71 ± 15.1 70 73 0.05
    Men (%) 45 46 45 0.78
    Caucasian (%) 73 73 74 0.9
Symptoms/Signs
    Chest pain 22 23 22 0.8
    Cough 17 20 15 0.16
    Edema 9 6 11 0.03
    Fever 7 7 7 0.88
Medical History
    Prior CHF 42 20 56 < 0.0001
    Prior MI 19 11 24 < 0.001
    Valvular Heart Disease 13 8 17 0.001
    Coronary Artery Disease 37 29 42 < 0.01
    Prior CABG/PCI 20 14 24 < 0.01
    COPD/Prior PE 17 17 17 0.99
    Systemic Hypertension 63 60 65 0.28
    Diabetes Mellitus 36 29 40 0.01
    Smoking History 18 19 17 0.44
Medications
   Spirinolactone 8 2 13 < 0.0001
   Digoxin 17 10 22 < 0.001
   Beta blocker 40 29 47 < 0.001
   ACE-I/ARB 43 34 49 < 0.001
   Loop diuretic 43 25 55 < 0.001
Other
   Hematocrit < 30 21 16 24 0.05
   eGFR < 30 16 14 17 0.45
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fication of Diet in Renal Disease method [13].
Determination of the diagnosis was made according to 
the Framingham Criteria for CHF [14] with the reviewing 
physician blinded to NT-proBNP determinations. The pri-
mary discharge diagnosis, secondary diagnosis and coded 
diagnosis from the patient visit was then reviewed to aid in 
the diagnosis of non-CHF events.
Measurement of Levels of NT-proBNP
NT-proBNP analysis was conducted using established meth-
ods  on  a  commercially  available  immunoassay  (Elecsys 
proBNP, Roche Diagnostics, Indianapolis, Indiana).
Statistical Analysis
Results  were  analyzed  using  standard  statistical  analysis 
including Mean (T-test), Kruskall-Wallis for medians, com-
parison of proportions for equality, and receiver operator 
curve (ROC) analysis. Commercially available SAS version 
9.1 was used for analysis. Concentrations of proBNP were 
highly  skewed  and  therefore  logarithmically  transformed 
before analysis. Resultant models were compared using log 
likelihood  chi  squared  tests.  Comparisons  of  NT-proBNP 
levels  across  diagnostic  categories  were  performed  using 
Kruskall-Wallis (non-parametric ANOVA) testing. The di-
agnostic performance of the assay was assessed by using 
receiver operating characteristic curves, formed by plotting 
sensitivity on the y axis and 1-specificity on the x axis for all 
possible cut off values of each diagnostic test.
The overall discriminatory ability of each test was shown 
by the area under the receiver operating characteristics curve. 
To test the accuracy in our cohort, the presence or absence of 
CHF was assessed based on the cut points derived from the 
previously pooled analysis [8]. We computed the sensitivity, 
specificity and diagnostic accuracy (defined as the sum of the 
concordant cells divided by the sum of all cells in two by two 
tables) of NT-proBNP measurements for all of the suggested 
cut-off  points.  Univariate  and  multivariate  analyses  were 
used to determine whether the peptide assay gave improved 
diagnosis  of  CHF  over  clinical  predictors  including  age, 
gender, hematocrit and renal failure.
 
Results
The 502 consecutive patients meeting inclusion criteria com-
prised the study population. Forty eight subjects were ex-
cluded due to incomplete data collection. The demographics 
for the study are shown in Table 1. The mean age was 71.4 
± 15.1 years (range 20-104 years). Forty five percent (226) 
were male and 55% (276) were female. Prior CHF was pres-
ent in 209 subjects (41.6%). Prior myocardial infarction was 
present in 18.5% and known coronary disease in 36.6% of 
Figure 1. Test Performance–Area Under the Receiver Operator Curve (ROC) Characteristics for Total Popu-
lation. Median NT-proBNP for total cohort: 3050 pg/ml; Median NT-proBNP for CHF group: 4935 pg/ml; 
Median NT-proBNP for non-CHF group: 1075 pg/ml.  CHF: Congestive Heart Failure.
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patients. CHF was diagnosed in 301 (60%) of our subjects.
The median NT-proBNP for the total cohort was 3050 
pg/ml. Figure 1 demonstrates the receiver operator charac-
teristics curve for the total population signifying test per-
formance. The area under the curve (AUC) for NT-proBNP 
was 0.73 (95% CI: 0.65-0.75). Among patients who had a 
diagnosis of CHF, the median NT-proBNP level was 4935 
pg/ml compared with 1075 pg/ml among patients without 
acute CHF (P < 0.001).
Table 2 shows the diagnostic analysis for the pooled in-
ternational collaborative trial cut-pointfs in our cohort for 
the diagnosis of CHF. The cumulative data demonstrated a 
sensitivity of 81% and a specificity of 53% in our popula-
tion, with a positive predictive value of 72% and a diagnostic 
accuracy of 70%. The diagnostic accuracy of NT-proBNP 
in our study appears somewhat inferior to the collaborative 
group’s findings (70% vs. 83%, respectively). Additionally, 
the negative predictive value of a single age-independent cut 
point of 300 pg/ml was also less (86%) in our study as com-
pared to 98% in the ICON study.
Univariate analysis was used to assess the diagnostic ac-
curacy of NT-proBNP for CHF according to age, the pres-
Figure 2. Test performance-area under the receiver operator curve (ROC) characteristics 
for age 50 or ≥ 50 years.














450 pg/ml 94 45 72 82 65
50-75 years
900 pg/ml 80 56 69 70 67
>75 years
1800 pg/ml 79 52 75 59 70
Cumulative 
Data 81 53 72 66 70
ICON: International Collaborative of NT-proBNP
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ence of renal disease or anemia. Age (> 50 years) and renal 
insufficiency (creatinine clearance of < 30 ml/min) corre-
lated directly with NT-proBNP levels, while anemia (hema-
tocrit < 30%) correlated inversely with NT-proBNP levels. 
Creatinine clearance estimated of < 30 ml/min did not, how-
ever, significantly affect the AUC or diagnostic accuracy of 
NT-proBNP, while age (> 50 years) shifted the AUC from 
0.83 to 0.73 (P ≤ 0.01). Anemia (hematocrit < 30%) had a 
borderline effect on the diagnostic accuracy of NT-proBNP, 
shifting the AUC from 0.75 to 0.64 (P = 0.08) (Fig. 2, 3). 
By multivariate linear regression both age and creatinine 
clearance were highly significant predictors of NT-proBNP 
levels (P < 0.0001), while hematocrit was of borderline sig-
nificance (P = 0.06). In a multivariate model including NT-
proBNP , age, prior CHF, anemia and renal insufficiency the 
best predictor of CHF was prior CHF, odds ratio (OR)    = 45; 
95% CI: 23-88. The OR for NT-proBNP remained significant 
(OR = 5; 95% CI: 2.5-10), while the OR for anemia was of 
borderline significance (OR = 1.7; 95% CI: 0.9-3.2).
Discussion
  
Our findings demonstrate that NT-proBNP determinations, 
although useful for the diagnosis of CHF in a complex el-
derly population with multiple comorbidities, may be less 
discriminating than previously thought. Although the diag-
nostic accuracy of age-adjusted NT-proBNP cut off values 
appears less robust in this population, the negative predic-
tive value of a single age-independent value of 300 pg/ml 
remained reasonably high at 86%. In multivariate analysis, 
prior CHF was the most potent predictor of CHF in an elderly 
emergency room population presenting with dyspnea. Utiliz-
ing age-adjusted algorithms derived from the Pride study, the 
ICON study reported a sensitivity of 90% and a specificity 
of 84% for NT-proBNP, with a negative predictive value of 
66%, a positive predictive value of 88% and diagnostic accu-
racy of 83% for CHF in a large pooled database [8]. Overall 
the collaborative results appear superior to our findings.
Compared to the ICON study, our cohort involved an 
older population (mean age 71 vs. 68 years) with a higher 
incidence of cardiovascular co-morbidities, especially prior 
CHF  (42%  vs.  34%,  respectively).  The  difference  in  the 
prevalence of prior CHF in our cohort as compared to the 
original PRIDE study (42% vs. 25% respectively) was even 
more striking. It is of particular interest that the accuracy 
of NT-proBNP in our study was nearly identical to that of 
Chung et al’s [10] study of patients with prior CHF (AUC 
0.73 vs. 0.75, respectively).
As advancing age is associated with reduced ventricular 
compliance [15] and glomerular filtration rates [16], it is not 
surprising that age has been previously shown to be directly 
Figure 3. Test performance-area under the receiver operator curve (ROC) characteristics 
for hematocrit.
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correlated with both BNP and NT-proBNP levels. Recent 
data has shown a close correlation between estimated GFR 
and NT-proBNP levels [17]. Both BNP and NT-proBNP are 
equally dependent on renal function for their clearance [18] 
and CKD may be associated with cardiac pathology of im-
portant clinical significance. Additionally, the prevalence of 
primary pulmonary causes of dyspnea was relatively low in 
our cohort (< 10%) as compared to the ICON study (37%). 
Finally, a final diagnosis of CHF was made in 35% of PRIDE 
subjects versus 60% of our subjects revealing further differ-
ences in these patient populations.
Several  other  recent  studies  have  also  suggested  that 
higher cut-offs should be used for elderly as compared to 
younger patients to improve specificity [19, 20]. Similarly, 
the diagnostic accuracy of NT-proBNP in these studies was 
significantly better than what was seen in our population. 
Utilizing cutoffs of 972 pg/ml and 2000 pg/ml, respectively 
for younger as compared to elderly patients in a population 
with a mean age of approximately 70 years, these authors 
obtained diagnostic accuracies of 91% and 83%, which are 
similar to the PRIDE and pooled data.
Although NT-proBNP performed similarly to BNP in 
the general population in detecting left ventricular dysfunc-
tion [21], a recent comparison of BNP and NT-proBNP in 
the diagnosis of CHF in patients age 65 and older [22] sug-
gested that NT-proBNP may be less useful in this population. 
Although there was a strong correlation between both natri-
uretic peptides in the general population, BNP determina-
tions were more accurate in the diagnosis of CHF. Similarly, 
concordance between the 2 natriuretic peptides was found in 
blood samples taken from an emergency room population, 
but renal impairment affected only the NT-proBNP results 
[23].
In our cohort although renal function correlated directly 
with  NT-proBNP  levels,  reduced  creatinine  clearance  did 
not affect the diagnostic accuracy of proBNP testing. Similar 
findings were noted in a subgroup analysis in PRIDE [24] 
where  the  area  under  the  ROC  remained  unchanged  in 
patients  with  moderate  renal  insufficiency  compared  to 
those with severe renal insufficiency. Similar data exists on 
the effect of creatinine clearance on the diagnostic accuracy 
of CHF for BNP [25-27]. Several studies have shown an 
independent effect of renal function on BNP in the absence 
of elevated left ventricular filling pressures [25, 26], while 
McCullough et al. reported that renal function influences the 
cut point for BNP in the diagnosis of CHF [27].
Hematocrit < 30% may also adversely affect the diag-
nostic accuracy NT-proBNP. Our data are consistent with 
the previously described inverse relationship of hematocrit 
to absolute NT-proBNP levels [28, 29]. A change in the area 
under the receiver operating curve from 0.75 to 0.64 (P = 
0.08) with a HCT < 30% demonstrates a potential confound-
ing factor affecting test accuracy. Willis et al. [30] showed 
that anemia was associated with elevated NT-proBNP above 
cut-off levels in adults without CHF or renal disease, while 
Muscari et al. [31] showed that the relationship between he-
matocrit and NT-proBNP was independent of echocardio-
graphic variables. Similarly, hemoglobin levels are indepen-
dent predictors of BNP levels in the absence of CHF [32].
NT-proBNP is a useful adjunct to clinical and radio-
graphic assessment of heart failure and provides prognostic 
information regarding re-hospitalization risk and mortality 
[33]. However, it is important to remember that the diagnos-
tic accuracy of any test should be validated for the specific 
population being studied. Individual hospitals should assess 
the diagnostic accuracy of natriuretic peptide assays in their 
specific patient populations to better understand the strengths 
and limitations of their use. Older subjects with an increased 
prevalence of prior CHF and cardiovascular disease, as well 
as anemia and renal disease, may have chronically elevated 
NT-proBNP levels which diminishes the positive predictive 
value for NT-proBNP in that population. Utilizing higher 
age-adjusted cut-off values for NT-proBNP may improve the 
positive predictive value of NT-proBNP, but may adversely 
affect the negative predictive value and overall diagnostic 
accuracy.
Limitations
Our study results are limited by the retrospective design of 
the trial and modest sample size from a single center. False 
negative NT-proBNP levels may also occur in obesity, but 
body mass index calculations were not available for analysis 
in our study. Our results may have also been biased by patient 
selection with a high prevalence of prior CHF patients. We 
analyzed only subjects in whom a NT-proBNP sample was 
drawn and NT-proBNP utilization in subjects with primary 
pulmonary pathology appears lower in our study as compared 
to  prior  reports.  Due  to  the  high  prevalence  of  cardiac 
morbidities and low prevalence of pulmonary morbidities, 
generalization of our results may be limited.  Patients were 
not followed prospectively after hospital discharge and thus 
the prognostic value of NT-proBNP could not be ascertained 
in our population.
Conclusion
The diagnostic accuracy of NT-proBNP in the evaluation of 
dyspnea utilizing current age-specific cut-points appears to 
be diminished as compared to prior studies in elderly sub-
jects with a high prevalence of prior CHF and cardiovascu-
lar comorbidities. Age, prior history of CHF and hemato-
crit levels appear to be the most important determinants of 
NT-proBNP diagnostic accuracy and deserve further study. 
Although renal insufficiency is associated with elevated NT-
proBNP determinations, creatinine levels do not appear to 
materially affect the diagnostic accuracy of the assay. Fur-
ther studies are needed in larger samples of patients to assess 
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the diagnostic accuracy of NT-proBNP in elderly subjects 
and the effect of prior cardiovascular disease, anemia, and 
renal function on assay performance.
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